TCF4 and plasma cell myeloma: Using CRISPR gene editing and/or the GO-203 inhibitor to silence MUC1 in multiple myeloma cells, MUC1-C was shown to activate MYC expression by binding to the promoter in a β-catenin/transcription factor 4-mediated mechanism [56].